​

Rationale

Many people with cancer will require pain relief with opioids at some time in their illness. Opioids are highly effective for most, but a group of people develop significant side effects. Currently there is no means of predicting who will get side effects. This study seeks to elucidate the clinical, biological and genetic factors that influence side effects and efficacy for the opioid drug class in a palliative care population of cancer patients.   

 

Key Aim    

•    To build a database of linked clinical phenotype, biological data, and genotype information from patients with cancer treated with opioids.
•    To establish if data collection to such a registry is feasible and acceptable. 

Potential Impact    

By establishing a clinical opioid pharmacogenomics registry for people with cancer, we are seeking to personalise the prescribing of opioids to improve pain relief and reduce suffering. 
        
Additional information    

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=377282&isReview=true

 

Key contact    

Leeanne Pasanen Leeanne.Pasanen@svha.org.au

 

Funding    

Victorian Comprehensive Cancer Centre (VCCC)

​

​